| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100765 | Journal of Crohn's and Colitis | 2009 | 7 Pages |
Abstract
Antibiotics, azathioprine/6-mercaptopurine, and conservative surgery are the mainstay of therapy for fistulizing Crohn's disease. Infliximab is a therapeutic option in patients without prior response to immunosuppressant therapy. In fibrostenotic Crohn's disease, endoscopic balloon dilation, if feasible, or surgical therapy should be considered. These expert recommendations are available online (www.epact.ch). Prospective evaluation is now needed to test the validity of these appropriateness criteria in clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Christian Felley, John-Paul Vader, Pascal Juillerat, Valérie Pittet, Colm O'Morain, Yves Panis, Boris Vucelic, Jean-Jacques Gonvers, Christian Mottet, Florian Froehlich, Pierre Michetti, the EPACT II Study Group the EPACT II Study Group,